Cardinal Health said revenue for the 3 months ended September 30, 2025 increased 22% to $64.0 billion from the prior-year period, citing growth in branded and specialty pharmaceutical sales from existing and new customers.

10-QQuarterly reportFiled Oct 30, 2025Period of report Sep 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

Cardinal Health said revenue for the 3 months ended September 30, 2025 increased 22% to $64.0 billion from the prior-year period, citing growth in branded and specialty pharmaceutical sales from existing and new customers.
The company said GAAP operating earnings for the 3 months increased 18% to $668 million and non-GAAP operating earnings increased 37% to $857 million, while GAAP and non-GAAP diluted EPS rose 11% to $1.88 and 36% to $2.55, respectively.
Cardinal Health said it announced on August 12, 2025 that it, through the Specialty Alliance, has entered into a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash, and that in connection with the closing it will issue common units in the Specialty Alliance to certain physicians and management estimated to have a grant date fair value of approximately $500 million.
The company said cash and equivalents as of September 30, 2025 were $4.6 billion and net cash provided by operating activities for the 3 months was $1.0 billion. During the same period, it deployed $500 million for debt repayment, $375 million for share repurchases, $129 million for dividends, and $108 million for capital expenditures.

Key figures

Quarter ended September 30, 2025

Revenue: $64.0B
Operating income: $668M
Net income: $450M
EPS: $1.88
Gross profit: $2.3B
Operating cash flow: $973M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly Revenue $64.0 billion, Up 22%

Cardinal Health said revenue for the 3 months ended September 30, 2025 increased 22% to $64.0 billion from the prior-year period, citing growth in branded and specialty pharmaceutical sales from existing and new customers.

Source · Based on the MD&A text of the filing

Operating Earnings and Diluted Earnings Per Share

The company said GAAP operating earnings for the 3 months increased 18% to $668 million and non-GAAP operating earnings increased 37% to $857 million, while GAAP and non-GAAP diluted EPS rose 11% to $1.88 and 36% to $2.55, respectively.

Source · Based on the MD&A text of the filing

Solaris Health Acquisition Agreement

Cardinal Health said it announced on August 12, 2025 that it, through the Specialty Alliance, has entered into a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash, and that in connection with the closing it will issue common units in the Specialty Alliance to certain physicians and management estimated to have a grant date fair value of approximately $500 million.

Source · Based on the MD&A text of the filing

Cash and Capital Deployment

The company said cash and equivalents as of September 30, 2025 were $4.6 billion and net cash provided by operating activities for the 3 months was $1.0 billion. During the same period, it deployed $500 million for debt repayment, $375 million for share repurchases, $129 million for dividends, and $108 million for capital expenditures.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.